We examined the effects of Herceptin, a bioengineered monoclonal antibody directed against Her-2/neu oncogene on skeletal metastasis using a xenograft model of breast cancer. Treatment of Her-2 overexpressing human breast cancer cells BT-474 with Herceptin caused a dosedependent decrease in cell proliferation. In in vivo studies, BT-474 cells (1 Â 10 5 ) were injected into the left ventricle of female BALB/c nu/nu mice. Intraperitoneal (i.p.) infusion of Herceptin (1 mg/kg twice a week for 5 weeks) from the day of tumor cell inoculation or at the time of radiologically detectable skeletal metastasis either slowed the development or prevented the progression of skeletal metastasis as compared to control groups of animals receiving nonspecific IgG. Bone histological analysis of long bones showed the ability of Herceptin to reduce the ratio of tumor volume to bone volume as well as mitotic index, effects that were more pronounced when Herceptin treatment was initiated from the day of tumor cell inoculation. While immunohistochemical analysis of long bones showed no difference in the production of Her-2, phosphorylated (P) Her-2 and MAPK, a significantly lower level of P-MAPK was seen in bones of Herceptin treated animals. These studies demonstrate the ability of Herceptin to inhibit the development and abrogate the progression of skeletal metastases associated with breast cancer by blocking the HER-2-mediated signaling pathways.
Introduction
Breast cancer is the most commonly diagnosed cancer in women, and is a major medical problem with profound health and social consequences (Margolese et al., 2003) . Despite recent advances in screening and early detection, breast cancer continues to result in a high incidence of morbidity and mortality (Bernstein, 2002) . In its late stage when tumor is refractory to hormone therapy, the majority of patients exhibit signs of destructive skeletal metastases (Mundy, 2002) . These effects are promoted by the production of cytokines, proteases and growth factors produced by tumor cells, which can induce tumor cell proliferation via their interaction with their respective receptors to initiate the vicious cycle of bone resorption within the tumor cell microenvironment (Pluijm et al., 2000; Roodman, 2003) . Inhibition of growth factors signaling through their receptors can therefore serve as a useful therapeutic approach to block bone metastases.
While several growth factors and their receptors have been implicated in this cascade, a large number of studies have demonstrated that epidermal growth factor (EGF) and its receptor (EGFR) are overexpressed and activated in breast cancer (Klijn et al., 1994) . These findings are of particular significance since Her-2 (ErbB2), a proto-oncogene belonging to the EFGR family, is found to be overexpressed in patients with breast cancer (Ross and Fletcher, 1998) . Being the preferred coreceptor for other members of this family, Her-2 is overexpressed in approximately 25-30% of human breast cancer patients (Kurebayashi, 2001 ). Such overexpression is correlated with poor clinical outcome including reduced disease-free and overall survival (Masood and Bui, 2002) . When Her-2 is overexpressed, signaling is mediated primarily by heterodimers between Her-2 and other members of the EGFR family. The heterodimers containing Her-2 have a particularly high ligand binding and signaling potency compared with non-Her-2 containing dimers (Zhou and Hung, 2003) . In addition, Her-2 undergoes a slower rate of ligandinduced endocytosis compared with other Her receptors. Therefore, signaling by Her-2 heterodimers is relatively prolonged, resulting in increased cell multiplication to further implicate this oncogene in breast cancer growth and metastases (Yarden, 2001) .
The biological characteristics of cancer cells along with the targeting properties of immune system offer a novel approach in the treatment of breast cancer, which overcomes the limitations of conventional methods (i.e. surgery, chemotherapy, and radiotherapy) by being 'selective' in its antitumor behavior. Although chemotherapy and hormone therapy are the most common modes of systemic therapy for breast cancer, an immunotherapeutic approach to its treatment has also shown promising results (Cheng et al., 2000) . Directed against Her-2 oncogene, the recombinant humanized monoclonal antibody, Herceptin, has shown significant clinical benefits as second/third-line monotherapy or first-line therapy when used in combination with chemotherapy for the treatment of Her-2 positive metastatic breast cancer (Bell, 2002) .
In the present study, we investigated the effects of Herceptin and its molecular mechanism of action in abrogating the development and progression of osteolytic bone metastases in an experimental mouse model of skeletal metastases using human breast cancer cells BT-474, which are known to express high levels of Her-2 (Moasser et al., 2001; Lacroix and Leclercq, 2004) . Specificity of the effect of Herceptin was established by monitoring the effect of Herceptin in nontumor bearing and animals inoculated with MDA-MB-231 cells, which do not overexpress Her-2.
Results

Effect of Herceptin on human breast cancer cell proliferation in vitro
Human breast cancer cell lines MDA-MB-231 and BT-474 were characterized for the levels of expression of Her-2. Western blot analysis showed marked overexpression of Her-2 in BT-474 breast cancer cells (Figure 1) . In order to evaluate the effect of Herceptin on cell proliferation, human breast cancers expressing low (MDA-MB-231) and high (BT-474) levels of Her-2 were treated with different doses (1.25-20.0 mg/ml) daily of Herceptin for 5 days. Herceptin had no significant effect on MDA-MB-231 cell proliferation. In contrast, Herceptin treatment resulted in a dose-dependent inhibition of BT-474 cell proliferation (Figure 2 ).
Effect of Herceptin on experimental skeletal metastasis
The effect of Herceptin on skeletal metastases was evaluated in an experimental xenograft model of breast cancer. Female Balb/c/nu.nu mice were inoculated with human breast cancer cells BT-474 (1 Â 10 5 ), which express high levels of Her-2 oncogene into the left ventricle. Animals were randomized and infused with 1 mg/kg twice weekly via Intraperitoneal (i.p.) injection with either nonspecific human IgG or Herceptin for 5 weeks from the day of tumor cell inoculation (protocol A) or following the development of skeletal metastasis visualized by X-ray at week 5 (protocol B) as described in Figure 3 . Initially, the effect of Herceptin administration on the development of bone metastases was examined using protocol A. Distinct skeletal lesions were seen in control group of animals receiving nonspecific IgG at week 10 post-tumor cell inoculation. In contrast, experimental animals receiving Herceptin either failed to develop any skeletal lesions or exhibited lesions of significantly smaller size compared to control group as assessed by radiography using X-ray analysis (Figure 4 ). Representative hind limb radiographs of a control and an experimental animal showed appearance of distinct skeletal lesions in the proximal tibia in the control animals, whereas minimal or no distinct skeletal lesions were seen in Herceptin-treated animal at week 10 posttumor cell inoculation (Figure 4) . Treatment with Herceptin resulted in a significant decrease in the total lesion area as compared to the animals receiving control IgG. Analysis of control and experimental tumors at week 5 showed lower incidence, smaller lesion area and number in animals receiving Herceptin (data not shown).
In order to effectively determine the metastatic tumor burden in the bone, histologic analysis of tibia removed from control and Herceptin-treated animals was performed. The presence of histologically detectable tumor cells was seen in both control and experimental animals; however, there was a significant decrease in the lesion area in mice treated with Herceptin ( Figure 5a ). Determination of tumor volume (TuV)/tissue volume (TV) ratio as described in 'Materials and methods' showed a significant decrease in tumor burden in experimental group of animals treated with Herceptin ( Figure 5b ). These results showed that Herceptin is highly effective at preventing the progression of BT-474 breast cancer bone metastases as observed by both radiological and histological analysis. Anti-Her-2 antibody P Khalili et al
Effect of Herceptin on established skeletal metastases
To evaluate the effectiveness of Herceptin on the progression of established skeletal metastases, we used protocol B as outlined in Figure 1 . All animals exhibiting skeletal metastasis at week 5 were selected, randomized and divided into two groups ( Figure 6a ). For the next 5 weeks, these animals were treated with either 1 mg/kg twice weekly nonspecific IgG or Herceptin. Effect of this treatment on the progression of skeletal metastases was evaluated at weekly intervals by X-ray analysis. At week 10 post-tumor cell inoculation and after 5 weeks of treatment, all control animals receiving nonspecific IgG showed continued progression of their skeletal metastases. In contrast, experimental animals receiving Herceptin exhibited either a decrease or complete arrest in the progression of their skeletal metastases ( Figure 6b ). While the total lesion area at the start of these studies, as defined in protocol B, was similar by radiographic analysis in control and experimental groups of animals, treatment with Herceptin for 5 weeks resulted in preventing any further increase in lesion area (Figure 6b ). Histological analysis of long bones of control animals showed the presence of extensive skeletal metastases where tumor cells filled the bone marrow space and caused the destruction of cortical and trabecular bone (Figure 7a ). In contrast, treatment with Herceptin resulted in significantly lower tumor volume (TuV)/tissue volume (TV) ratios (Figure 7b ). In order to establish the specificity of Herceptin in blocking the progression of experimental skeletal metastases via the Her-2 signaling pathway, we also utilized MDA-MB-231 human breast cancer cell line that does not overexpress Her-2 (Moasser et al., 2001; Duivenvoorden et al., 2002) . Following the inoculation of MDA-MB-231, animals were treated with either control nonspecific human IgG or Herceptin as described in protocol A. X-ray examination showed the presence of experimental skeletal metastases at week 5 in both control and Herceptin treated groups, which continued to show a progressive increase in lesion area and number up to week 10 post-tumor cell inoculation (Figure 8a ). Analysis of radiographs from both groups of animals did not show any statistically significant change in lesion area following treatment with Herceptin in these non-Her-2 overexpressing cells (Figure 8b) . Similarly histologic analysis of long bones showed no decrease in TuV following treatment with Herceptin (data not shown).
To rule out the possibility of immune response that can be attributed to the effects on tumor metastases following treatment with Herceptin, we evaluated the effect of Herceptin on normal nontumor bearing MDA-MB-231 cells via intracardiac route and treated with 1 mg/kg twice weekly of control IgG (CTL) or Herceptin from the day of tumor cell inoculation for 5 weeks. Representative radiograph of long bones of control and experimental animals at weeks 5 and 10 post-tumor cell inoculation is shown in panel a. Area of skeletal lesions in control and Herceptin treated animals at weeks 5 and 10 is marked by arrows and was scored as described in 'Materials and methods' (b). Results are representative of 12 animals in each group, which were individually subjected to radiographic analysis Anti-Her-2 antibody P Khalili et al animals. Under experimental conditions described in protocol A, treatment with either control IgG or Herceptin failed to show any change in bone remodeling as assessed by radiological and bone histomorphometric analysis (data not shown).
Effect of Herceptin on BT-474 tumor cell mitotic index
Since Her-2 activation promotes tumor cell proliferation, we evaluated the effect of Herceptin on bone metastatic BT-474 breast cancer cell growth in vivo. This was achieved by manually counting mitotic cells and by immunohistochemical analysis, using an antibody against the proliferation marker Ki67 on histological sections of control and experimental sections generated by using protocol A and B. Mitotic index and Ki67 expression were significantly reduced in both studies when Herceptin treatment was initiated either from day 0 or at week 5 when skeletal metastases were established. However, these effects were more significant in Herceptin treated group of animals from protocol A when treatment was initiated at the time of tumor cell inoculation (Figure 9 ).
Effect of Herceptin on Her-2 mediated signaling pathway
In order to define the molecular mechanism of Herceptin mediated effect on blocking the development of skeletal metastases, histological sections of control and experimental animals treated with Herceptin were analysed by immunohistochemistry by determining the levels of production of Her-2, phosphorylated (P) P-Her-2, MAPK and P-MAPK. These studies showed no significant change in the levels of production of Her-2, Anti-Her-2 antibody P Khalili et al P-Her-2 or MAPK between control and experimental animals when Herceptin treatment was initiated at day 0, which resulted in a significant decrease in skeletal metastases as seen by radiological and histological analysis. However, due to the ability of Herceptin to block phosphorylation of MAPK (P-MAPK) histological sections of experimental animals receiving Herceptin exhibited a significantly lower level of production of P-MAPK (Figure 10 ). Under similar experimental conditions, analysis of histological sections of nonHer-2 overexpressing MDA-MB-231 tumors from animals treated with control IgG or Herceptin had no significant change in the levels of expression of Her-2, P-Her-2, MAPK or P-MAPK (data not shown).
Discussion
Despite the advances in the last two decades in elucidating breast cancer biology, understanding the complex multistep process of metastatic progression of this common malignancy to the skeleton and its control continues to be an elusive goal. In the present study, we directly evaluated the efficacy of Herceptin in abrogating the development and progression of established skeletal metastases using a xenograft model of breast cancer. The dose of Herceptin used in the current study has previously been shown to reduce tumor growth in vivo (Baselga et al., 1998) . The in vivo model used in the current study is well characterized and has been extensively used by us and others (El Abdaimi et al., 2000; Duivenvoorden et al., 2002; Mundy, 2002; Rabbani et al., 2005) . In this model, implantation of estradiol pellets has been shown to provide a supportive role for breast cancer cell growth (Shafie and Grantham, 1981) . However, due to the well described role of estradiol in bone remodeling and its interaction with Her-2 and in order to rule out the unlikely but possible interference of short-term estradiol administration in a bone metastasis model, the estradiol pellets were implanted uniformly in all experiments. We have used estrogen receptor (ER) positive human breast cancer cells BT-474 since they are known to endogenously produce high levels of HER-2. Furthermore, the antitumor effects of Herceptin have been demonstrated in HER-2 overexpressing cell lines regardless of their ER status (Baselga et al., 1998; Normanno et al., 2002) .
To evaluate the effectiveness of Herceptin, we used two experimental protocols as outlined in Figure 1 . In protocol A where Herceptin treatment was initiated at the time of tumor cell inoculation, 5 weeks of treatment with Herceptin resulted in a significant decrease in the number of animals developing skeletal metastases and a reduction in skeletal lesion area as compared to vehicle treated control groups. Although treatment was stopped after 5 weeks, these antitumor effects of Herceptin were maintained until week 10 post-tumor cell inoculation as compared to animals receiving nonspecific IgG. However, this response was less robust in protocol B when a similar therapeutic approach was used to block the progression of established skeletal metastases. To effectively assess the therapeutic response, we applied several criteria including radiological analysis, bone histology and evidence of any side effects of this treatment. Since Herceptin does not have efficacy in Her-2 negative patients, we did not see any statistically significant change in the incidence or Anti-Her-2 antibody P Khalili et al degree of skeletal metastases in animals inoculated with non-Her-2 overexpressing MDA-MB-231 cells following Herceptin treatment (Moasser et al., 2001) . These results are in agreement with previous reports where Herceptin was effective in reducing the growth of Her-2 overexpressing BT-474 and not MDA-MB-231 cells in vivo (Baselga et al., 1998; Mayfield et al., 2001) . By treating nontumor bearing animals with either control nonspecific IgG or Herceptin under similar experimental conditions, we have ruled out the nonspecific effect of Herceptin on bone via an immune response. From a mechanistic point Herceptin is known to inhibit tumor growth via several potential mechanisms, including antibody dependent cell-mediated cytotoxicity (ADCC), downregulation of Her-2, cell cycle arrest at G1 phase, induction of p27 preventing Her-2 cleavage, and blocking tumor associated angiogenesis (Sliwowski et al., 1999) . In our studies, Herceptin exhibited a marked change in tumor cell mitotic index and downregulation of Her signaling pathway. The ability of Herceptin to exhibit more significant antimitotic effects as seen in protocol A and maintenance of these effects during these studies can be attributed to the early initiation of treatment and the ability of Herceptin to inhibit several intracellular signaling pathways involved in tumor progression. In agreement with previous studies, Herceptin was selectively able to decrease P-MAPK without changing MAPK, Her-2 or P-Her in BT-474 cells (Yakes et al., 2002) . These effects of Herceptin on skeletal metastases are of particular interest since a potential limitation in developing effective therapeutic regiment for skeletal metastases could be the low bioavailability of these agents in the skeleton.
This study clearly demonstrates the ability of this targeted therapeutic approach in limiting the development of skeletal metastases and underscores the need to identify and initiate such therapy at the earliest time point in patients who are Her-2 positive. Furthermore, these results warrant the use of such an approach even in late stages of disease where any reduction in skeletal tumor burden is likely to have a direct impact on tumor associated morbidity by reducing bone metastases associated pain and fractures. Combining immunotherapy with chemotherapeutic agents like anthracyclines and taxanes has shown benefit in reducing tumor burden; however, the effect of these approaches on blocking skeletal metastases needs to be investigated (Baselga et al., 1998; Esteva et al., 2001) . In order to improve targeted delivery of these agents, additional studies are warranted using cytotoxic conjugates alone or encapsulated into liposomes, which have already shown their effectiveness to improve delivery and bioavailability (Park et al., 2002) . An area of caution in using such an approach remains the expression of Her-2 in normal tissue, where it may not only promote an immune response but can also localize these cytotoxic conjugates in normal cells. However, due to significantly higher level of expression of Her-2 in tumor cells, this approach may be effective by decreasing the availability of these agents to normal tissues and avoiding drug resistance.
In conclusion, results from this study have demonstrated the benefit of Herceptin in blocking breast cancer associated skeletal metastases in Her-2 positive tumors. Since Herceptin is currently indicated in hormone refractory metastatic breast cancer, results presented here provide the rationale to initiate this treatment at an early time point. This can be done at the time of establishment of Her-2 positive status of tumor cells and will lead to prevention of developing skeletal metastases, which occur in the later stages of the disease. In summary, use of such immunotherapeutic regimens alone and in combination with chemotherapeutic and antiangiogenic agents can prove to be of benefit in decreasing breast cancer associated morbidity and mortality.
Materials and methods
Cells and cell culture
Human breast cancer cell line BT-474 and MDA-MB-231 were obtained from American Type Tissue Culture Collection (Rockville, MD, USA) and maintained as described previously (Mayfield et al., 2001; Duivenvoorden et al., 2002) . Herceptin was a gift from Genentech Inc., San Francisco, CA, USA.
Cell proliferation assay and Western blotting
MDA-MB-231 and BT-474 cells were plated in triplicate at a density of 5000 cells/well in 100 ml media in flat bottom 96-well plates. Cells were grown in 10% FBS to 20-30% confluence and changed into serum-free medium overnight to bring them to a quiescent stage. Cells in triplicate wells were cultured for 5 days in the presence of 2% FBS with vehicle alone or different concentrations (1.25-20.0 mg/ml) of Herceptin. At the end of this period, effect on cell proliferation were determined by semiautomated colorimetric MTT dye reduction assay. Briefly, 10 mg of 5 mg/ml MTT was added to each well and the plates were incubated for 2 h at 371C in 5% CO 2 . Media was then removed and replaced with 105 ml DMSO to dissolve the purple crystals. Absorbance was measured by a photometric microplate reader (BMG Fluostar Optima, Munich, Germany) at 550 nm within 30 min.
For Western blotting, MDA-MB-231 and BT-474 (1 Â 10 6 ) cells were plated in 100 mm Petri dishes for 24 h. Cells were then washed with cold PBS and lysed with 200 ml of cold lysis buffer (150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 50 mM Tris-HCl pH 7.2, 0.2 mM sodium vanadate, 1% PMSF, 0.2% aprotinin). After keeping them on ice for 20 min, supernatants were collected by centrifugation at 13 000 g for 20 min, and the protein concentrations were determined. Cell lysates were resolved on 10% SDS-PAGE, transferred onto nitrocellulose membranes. Expression of Her-2 and b-tubulin as control were determined using anti-Her-2 (neomarkers; Lab Vision Corporation, Neomarkers Ab-15, Fremont, CA, USA; b-tubulin; BD BioSciences, Mississauga, ON, Canada).
Animal model
Female Balb/c/nu.nu mice (5 weeks old (15-20 g)) (Charles River, St Constant, QC) were used throughout the course of the studies. One day before tumor cell inoculation, all animals Anti-Her-2 antibody P Khalili et al were implanted with 21-day-release 0.25 mg estradiol pellet (Innovative Research of America, Sarasota, FL, USA) via s.c. route using a trocar (Shafie and Grantham, 1981) . For tumor cell inoculation animals were anesthetized by xylazine/ketamine mixture, and 1 Â 10 5 BT-474 or MDA-MB-231 cells were injected in 0.1 ml of cell suspension into the left ventricle of heart using a 26-gauge needle (Shafie and Grantham, 1981) . Following tumor cell inoculation, animals were treated with 1 mg/kg nonspecific purified human IgG (Sigma, St Louis, MI, USA) or Herceptin via i.p. route twice weekly for 5 weeks (protocol A). Alternatively following tumor cell inoculation, all animals were evaluated for the development of skeletal metastases as described below. At the time of development of skeletal metastases, animals with similar degrees of skeletal metastases were selected, which comprised 70% of total animals inoculated with tumor cells. These selected animals were randomized, and treated with 1.0 mg/kg twice weekly with nonspecific IgG or Herceptin via i.p. route (protocol B) (Baselga et al., 1998) . In other studies, normal nontumor bearing animals were injected with nonspecific human IgG or Herceptin for 5 weeks.
Radiological and histological analysis X-ray quantification High-resolution whole-body radiographs of animals were obtained under ketamine/xylazine anesthesia with the animals placed in a prone position against films (18 Â 24 cm 2 ; Mamoray Screens, AGFA, Mortsel, Belguim) and exposed to X-ray at 26 kV for 8 s using a Mammo Diagnost UC (Philips, Hamburg, Germany). X-ray films were processed in a Curix Compact processor (AGFA). The analyses were carried out in both femora and tibia of all animals using an image analysis system following digital capture of radiographic prints. The area and number of skeletal lesions was determined in all of the control and experimental groups of animals by careful evaluation of radiographs at the end of these studies using BioQuant image analysis software, version 6.50.10 (BioQuant Image Analysis corporation, Nashville, TN, USA). Results are presented as lesions area in mm 2 . All radiographs were carefully evaluated by at least three investigators, including one radiologist, who were blinded to experimental protocols. At the end of these studies, all long bones were removed and subjected to histological analysis (Duivenvoorden et al., 2002) . To reduce possible variation in analysis, four to six levels of each bone were cut and each level was assessed to get to the mid portion of bone with maximum tumor burden, which was considered as a representative section. Histologic measurement of total TuV was carried out in representative sections of both tibia of the animals treated with nonspecific IgG or Herceptin in both protocol A and B. The analysis was performed on the region 1 mm below the growth plate with OsteoMeasure system (Osteometrics Inc., Atlanta, USA) using an IBM compatible computer. The TuV and TV was measured and the percentage of TuV in total TV was calculated (El Abdaimi et al., 2000) .
Immunohistochemical analysis was carried out using antibodies against HER-2, P-HER-2 (NeoMarkers, CA, USA), MAPK and P-MAPK (Cell Signaling Inc., Beverly, MA, USA) as previously described (DiGiovanna et al., 1998; Adewale et al., 2002) .
Determination of mitotic index was carried out in H&E stained sections of long bones removed from control and experimental animals. Number of mitotic figures in tumor cells was counted in 10 randomly selected fields of vision under high magnification ( Â 400). Total mitotic index was established as a percentage of total tumor cells by blinded evaluation to the origin of the slides (Bendre et al., 2002) .
Statistical analysis
All results are expressed as mean7s.e.m. Statistical significance of the difference in numbers of osteolytic metastases and TuV between control and Herceptin treated groups were analysed by Mann-Whitney test for nonparametric samples and tumor progression was analysed by Kaplan-Meier.
